Skip to main content

Table 4 Baseline clinical and demographic predictors of uveitis in 435 participants in the Nordic juvenile idiopathic arthritis (JIA) cohort

From: Incidence and predictors of Uveitis in juvenile idiopathic arthritis in a Nordic long-term cohort study

 

No uveitis

Uveitis

OR (95% CI)

N

n (%)

N

n (%)

 

Female gender

346

227 (65.6)

89

59 (66.3)

1.0 (0.6, 1.6)

Oligoarticular onset

346

168 (48.6)

89

41 (46.1)

0.9 (0.6, 1.4)

Age at onset (< 7 years)

346

189 (54.6)

89

64 (71.9)

2.1 (1.3, 3.5)

ANA positive

340

79 (23.2)

87

37 (42.5)

2.4 (1.5, 4.0)

AHA > 15 U

112

14 (12.5)

22

9 (40.9)

4.8 (1.8, 13.4)

HLA-B27 positive

325

62 (19.1)

87

25 (28.7)

1.7 (1.0, 2.9)

ESR > 20 mm/H

276

95 (34.4)

78

34 (43.6)

1.5 (0.9, 2.5)

CRP > 10 mg/L

276

77 (27.9)

74

27 (36.5)

1.5 (0.9, 2.6)

DMARD use ≤ 2nd visita

316

111 (35.1)

34

14 (41.2)

1.3 (0.6, 2.7)

  1. aIn 350 children with no uveitis at the time of 2nd study visit, percentage of DMARD used within 2nd visit (median 13 (1st q 12, 3rd q 14) months) in children with no uveitis versus children with uveitis during further follow-up.
  2. Odds ratio (OR) of developing uveitis calculated with logistic regression. Oligoarticular onset, oligoarticular category 6 months after onset of disease, according to the International League of Associations for Rheumatology (ILAR) classification criteria (5); ANA antinuclear antibodies measured by immunofluorescence on Hep-2 cells two positive tests taken > 3 months apart in participants with one or more tests taken
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096